1298 related articles for article (PubMed ID: 28488245)
1. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
[TBL] [Abstract][Full Text] [Related]
2. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
3. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
4. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
[TBL] [Abstract][Full Text] [Related]
5. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
6. Optimizing intracellular signaling domains for CAR NK cells in HIV immunotherapy: a comprehensive review.
Zenere G; Olwenyi OA; Byrareddy SN; Braun SE
Drug Discov Today; 2019 Apr; 24(4):983-991. PubMed ID: 30771481
[TBL] [Abstract][Full Text] [Related]
7. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
9. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
[TBL] [Abstract][Full Text] [Related]
10. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
11. Natural Killer Cells: Angels and Devils for Immunotherapy.
Martín-Antonio B; Suñe G; Perez-Amill L; Castella M; Urbano-Ispizua A
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28850071
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.
Han EQ; Li XL; Wang CR; Li TF; Han SY
J Hematol Oncol; 2013 Jul; 6():47. PubMed ID: 23829929
[TBL] [Abstract][Full Text] [Related]
13. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.
Zhang J; Zheng H; Diao Y
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646574
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
Yilmaz A; Cui H; Caligiuri MA; Yu J
J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
[TBL] [Abstract][Full Text] [Related]
15. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
16. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Hu Y; Tian ZG; Zhang C
Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
[TBL] [Abstract][Full Text] [Related]
18. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
[TBL] [Abstract][Full Text] [Related]
19. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
Zhao Y; Zhou X
Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]